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Background: Surgical treatment of colorectal liver metastases has become increasingly aggressive. The
influence of this more active surgical approach on patients’ health-related quality of life (HRQoL) has
hardly been evaluated. This study investigated the impact of surgical and systemic treatment on HRQoL
in patients undergoing hepatic resection for colorectal metastases.
Methods: A total of 145 patients with colorectal liver metastases were entered prospectively into
the study. Based on HRQoL values derived from the EuroQol – 5D, health summary measures were
calculated to express the overall impact on four distinct clinical states. The HRQoL instrument was used
at baseline, 3 and 6 weeks after surgery, and every 3 months thereafter for up to 3 years.
Results: Patients showed a clear deterioration in HRQoL in the first weeks after surgery, followed
by a recovery to baseline levels at 3 months after potentially curative surgery. In contrast, a sustained
decline was noted when initial surgery for colorectal liver metastases was considered futile and palliative
chemotherapy was started immediately. Three years after initial surgery, there were distinct differences
in HRQoL between patients with or without recurrence. The latter group still had HRQoL scores at
baseline levels, whereas patients with tumour recurrence showed a significant deterioration in HRQoL.
Remarkably, there was no decline in HRQoL in patients with recurrent disease who could be treated by
secondary surgical intervention.
Conclusion: Superior overall HRQoL in the first 3 years after initial successful surgical intervention
merits an aggressive surgical approach and intensive follow-up to detect recurrence early.
Paper accepted 26 October 2010
Published online 15 December 2010 in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.7365
Introduction
Colorectal cancer is the third commonest cancer and
the second most frequent cause of cancer-related death.
Worldwide, approximately half a million people die from
colorectal cancer every year1. Liver metastases develop in
40 per cent of all patients with colorectal cancer2 and,
if metastatic disease is limited to the liver, resection
is the curative treatment of choice. Survival rates of
40–50 per cent for the ﬁrst 5 years after initial treatment
have been reported3,4.
For many years, outcomes of medical treatments in
cancer were expressed primarily in terms of survival and
disease-free status. Changes in health policy have shifted
the emphasis of health evaluation from traditional, easy-to-
measure clinical indicators to more complex patient-based
outcomes such as quality of life. Today, it is increasingly
acknowledged that quality of life, or rather health-related
quality of life (HRQoL), is an important additional
outcome measure in the assessment of oncological surgery
and systemic treatment5–7.
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Several studies have already addressed long-term
HRQoL in primary colorectal cancer8–11. However, few
data are available on HRQoL after surgery for metastatic
colorectal cancer12. As contraindications for surgical
treatment of metastatic disease are increasingly being
abandoned and local ablative techniques are upcoming
treatment modalities, an increasing number of patients are
qualifying for aggressive treatment13. Although considered
important in this context, data on HRQoL in this patient
category are scarce in the current literature.
Most HRQoL instruments measure multiple domains
(for example European Organization for Research and
Treatment of Cancer (EORTC) QLQ-C30) and are
therefore commonly indicated as descriptive proﬁle
measures. In contrast, a distinguishing feature of a value-
based HRQoL instrument is its potential to assign a single
metric ﬁgure to a speciﬁc health status.
Such value-based HRQoL instruments produce out-
comes that can be incorporated into health summary
measures such as quality-adjusted life years (QALYs) and
the Quality-adjusted Time Without Symptoms of disease
and Toxicity of treatment (Q-TWiST). Health summary
frameworks produce an outcome measure that combines
the effects of health interventions on mortality and mor-
bidity into a composite measure of health beneﬁt14.
The aim of this prospective study was to describe
long-term HRQoL comprehensively by the use of health
summary frameworks in patients undergoing surgical
treatment of colorectal liver metastases.
Methods
Patients were enrolled in a prospective multicentre trial
between May 2002 and February 2006. Four surgical
departments with experience in liver surgery participated
in this trial. Patients were required to have a history of
proven colorectal cancer treated by surgical resection and
suspicion of up to four potentially resectable colorectal liver
metastases without evidence of extrahepatic metastatic dis-
ease on contrast-enhanced computed tomography and/or
ﬂuorodeoxyglucose–positron emission tomography. The
study was approved by the ethics committees of all partici-
pating centres, and all patients provided written informed
consent.
Laparotomy for hepatic resection was generally per-
formed within 4 weeks after inclusion (range 1–7 weeks).
Surgical treatment was performed only if it was deemed
feasible to remove all liver lesions adequately. Resec-
tion of an isolated extrahepatic intra-abdominal lesion
was performed, but further surgical treatment of any
other extrahepatic disease discovered during laparotomy
was carried out at the surgeon’s discretion. After hepatic
surgery, patients did not receive any standard (adjuvant)
chemotherapy. Follow-up lasted for 3 years after the initial
intervention.
None of the patients received preoperative chemo-
therapy. Chemotherapy was started only in the event
of unresectable disease or tumour recurrence that was
not amenable to surgical reintervention. During the study
period systemic chemotherapy consisted of 5-ﬂuorouracil,
leucovorin and oxaliplatin as ﬁrst-line and irinotecan as
second-line treatment. From 2005, bevacizumabwas added
to the standard chemotherapy regimen.
Clinical management and perioperative ﬁndings were
documented prospectively in standard case record forms.
For assessment of HRQoL, futile laparotomy was deﬁned
as any laparotomy that did not result in surgical treatment
of liver metastases, either because of extrahepatic disease or
because liver involvement was too extensive and resection
would lead to an insufﬁcient liver remnant. Hence, patients
were categorized in two groups: one in which surgery
was considered curative (curative surgery group) and the
other in which surgery was considered futile (non-curative
group) because complete resection of all tumour lesions
during laparotomy was not considered possible.
Health summary frameworks
The QALY was used as a health summary measure15,16.
It comprises two key elements, which together express
health, namely the quantity and the quality of life lived.
Apart from the QALY, the Q-TWiST method was used as
a particularly promising alternative approach to expressing
the overall impact of medical interventions in the setting of
cancer treatment17,18. The objective of the Q-TWiST
method, similar to the QALY method, is to include
patientmortality (survival) andHRQoL in a single analysis.
However, in the Q-TWiST method HRQoL is expressed
for a limited number of distinct clinical health states (see
statistical analysis section for computational strategy).
Health-related quality-of-life instrument
The EuroQol – 5D (EQ-5D
TM
; EuroQol Group, Rot-
terdam, The Netherlands), a widely applied and validated




domains: mobility, self-care, usual activities, pain and
discomfort, and anxiety and depression19. Each attribute
is rated at three levels: no problems, some problems
or severe problems. The EQ-5D
TM
index or value is
obtained by applying predetermined weights to the ﬁve
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domains derived from the general public. This results in
a society-based quantiﬁcation of the respondents’ health
status or HRQoL on a scale of 0 (dead) to 1 (perfect
health)20. Furthermore, the respondents were asked to
rate their overall HRQoL on a visual analogue scale
(EQ-5D
TM
VAS) consisting of a vertical line ranging
from 0 (worst imaginable health status) to 100 (best
imaginable), representing the patients’ perspective. As
these two measures (society based and patient based)
are expressed on an absolute scale capturing the whole
continuum of HRQoL, differences of 1–2 per cent can
be considered as clinically important. Baseline EQ-5D
TM
forms were completed in hospital, and subsequent forms
were sent to the patient’s postal address 3 and 6 weeks after
surgery, and every 3 months thereafter for the next 3 years.
If forms were not returned within 2 weeks, a telephone or
written reminder was sent.
Statistical analysis
For Q-TWiST analyses all patients were distributed over
four categories, representing the main clinical states of
patients with colorectal cancer after initial treatment of
liver metastases: death, the state after non-curative surgery,
the state after curative surgery with recurrent disease, and
the disease-free state after curative surgery. For each state,
the proportion of patients was calculated for the entire
follow-up period of 3 years. Patients could shift between
states in a certain order (Fig. 1). Next, meanHRQoL values
were determined for each of the four clinical states based
on the EQ-5D
TM








Fig. 1 State transition diagram for patients in possible clinical
health states
of time was expressed as the interval between two measure-
ments. Finally, for each clinical state themean duration was
multiplied by the corresponding mean HRQoL value and
the proportion of patients. This resulted in the number of
QALYs accumulated for each clinical state during 3 years
of follow-up. One-way ANOVA was applied to test for
differences between groups at various measurement points
(ad hoc multiple comparison test; Scheffe´ test). All statistical
analyses were performed with SPSS statistical software
version 17.0 (SPSS, Chicago, Illinois, USA).
Results
A total of 145 patients were included in the study.
Seven patients were excluded from further analysis
because ﬁnal histology after laparotomy demonstrated
the presence of benign liver lesions without evidence of
metastatic colorectal cancer. Thus, 138 patients underwent
laparotomy for potentially curative resection of proven
liver metastases. The general demographics (sex ratio,
mean age) and tumour characteristics (primary cancer site,
tumour status, node status) of this group are summarized
in Table 1. Before intervention, 136 (98·6 per cent) of
the 138 patients completed the EQ-5D
TM
instrument;
this group was analysed prospectively. After 3 years the
overall response rate was 90·8 per cent (1852 forms of
2040 possible responses).
Distribution of the four clinical states
The four clinical groups representing the main clinical
status options (death, non-curative surgery, curative
surgery with recurrent disease, and curative surgery with
disease-free status) and their distribution over time are
Table 1 Demographics and tumour characteristics
No. of patients*
Mean (range) age (years) 63 (33–80)
Sex ratio (F :M) 44 : 94






No. of hepatic tumour(s)‡
1 82
2–4 56
Median (range) size of largest lesion (mm) 35 (6–160)
*Unless indicated otherwise. †Interval between diagnosis of primary
tumour and hepatic metastases. ‡As seen on preoperative computed
tomography.
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Time after initial laparotomy (months)
Fig. 2 Proportion of patients in each of the four clinical states
over time in the ﬁrst 3 years after initial hepatic resection for
colorectal metastases (patients may have moved from one state to
another over the course of the study)
depicted in Fig. 2, representing the Q-TWiST. The
states ‘disease-free’ and ‘non-curative’ were the main
groups in the ﬁrst few months. In the course of
the study, the percentage of patients with ‘recurrence’
and ‘death’ obviously increased. In total, 117 patients
(86·0 per cent) underwent successful surgical intervention
(curative group), whereas 19 (14·0 per cent) had a non-
curative laparotomy because of inoperable disease at the
time of surgery. Disease-free survival of all 136 patients at 2
and 3 years was 32·4 per cent (44 of 136) and 27·9 per cent
(38 of 136) respectively. The median time to disease
recurrence was 8·5 (range 0–75) months. For patients with
recurrent disease and no option for surgical reintervention,
chemotherapy was started at a median of 12·0 (range
1–36) months after hepatic resection.
Health-related quality of life associated with the
four clinical states
Three weeks after surgery, all patient groups showed a
clear decrease in HRQoL, as expressed in the EQ-5D
TM
values. Thereafter, HRQoL values for three of the clinical
groups showed distinct patterns over time (death has a
value of 0 by deﬁnition). In general, disease-free patients
had the bestHRQoL, whereas patients who had undergone
non-curative surgery were doing worse than patients with
recurrent disease (Fig. 3). Statistically signiﬁcant overall
effects (all differences exceeding 2 per centwere considered
clinically signiﬁcant) were observed between the disease-
free and non-curative groups from week 12 onwards
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Fig. 3 Mean index value of patients’ health calculated by the
EuroQol – 5D for each clinical health state in the ﬁrst 3 years
after initial resection of hepatic colorectal metastases. The area
under the curve corresponds to the number of quality-adjusted
life years. Error bars represent standard errors. HRQoL,
health-related quality-of-life. Asterisks indicate statistically
signiﬁcant effects (P < 0·050), reported only if the number of
observations exceeded ten (one-way ANOVA)
disease-free and recurrence groups at the end of follow-up
at 144 weeks (P = 0·024). The non-curative surgery and
recurrence groups showed an identical pattern of HRQoL
values (Fig. 3). The HRQoL of the group with recurrent
disease was intermediate between that of the non-curative
and curative surgery groups.
Separate analyses were performed within the recurrent
disease group for patients whose recurrence was treated
by further surgical intervention and those who received
chemotherapy (Fig. 4). HRQoL in patients treated by
further surgical resection was signiﬁcantly better after
52 weeks than in the group receiving chemotherapy. EQ-
5D
TM
VAS scores (patients’ perception) showed a pattern
for all clinical groups similar to that of the society-based
EQ-5D
TM
values (data not shown).
Quality-adjusted life years
From the mean HRQoL values for each clinical state
(Table 2), it was clear that the disease-free group fared bet-
ter than the group that had non-curative surgery or those
who developed recurrent disease. Furthermore, when sur-
gical reintervention for recurrence seemed feasible, the
HRQoL was comparable to that in the group in which no
recurrence occurred. Separate analyses were performed to
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Fig. 4 Mean index value of patients’ health calculated by the
EuroQol – 5D for the subgroups with recurrent disease treated
by (repeat) surgery or chemotherapy in the ﬁrst 3 years after
initial resection of hepatic colorectal metastases. The area under
the curve corresponds to the number of quality-adjusted life
years. Error bars represent standard errors. HRQoL,
health-related quality-of-life. Asterisks indicate statistically
signiﬁcant effects (P < 0·050), reported only if the number of
observations exceeded ten (one-way ANOVA)
Table 2 Mean health-related quality-of-life values for each






Death 0(0) 349 0 0
Disease-free 0·78(0·23) 891 0·92 −0·59
Non-curative 0·67(0·31) 162 0·92 −0·59
Recurrence 0·74(0·25) 450 0·92 −0·59
Without 0·82(0·17) 205 0·92 −0·43
chemotherapy
With 0·68(0·28) 245 0·92 −0·59
chemotherapy
*Scale is from 0 (death) to 1 (perfect health). HRQoL, health-related
quality of life.
express the number ofQALYs gained for each clinical state;
the disease-free group accumulated 0·78 QALYs annually
over 3 years, the non-curative group 0·67 QALYs annually
and recurrence group 0·74 QALYs annually (Table 2). A
total of 2·18 QALYs were collected in 3 years, whereas a
total of 3·0 QALYs could theoretically have been achieved
if all patients had been in perfect health for the 3-year dura-
tion of follow-up. Additionally, Table 2 shows a difference
of 14·0 per cent between recurrence subgroups, one treated
with chemotherapy (0·68 QALYs) and the second surgi-
cally, without additional chemotherapy (0·82 QALYs).
Discussion
This paper describes the results of 3 years of global
HRQoL measurement in patients who had initial surgical
intervention for colorectal liver metastases and different
subsequent treatments. Initially the patients showed a clear
overall deterioration inHRQoL during the ﬁrst weeks after
surgery, in line with previous observations12. Thereafter,
four distinct clinical health states were distinguished, each
of which showed distinct patterns in terms of HRQoL out-
come. Disease-free patients performed signiﬁcantly better
than patients who underwent non-curative surgery or
patients with recurrent disease. The inferior HRQoL in
patients with recurrent disease may be attributed to the
knowledge of progressive disease as well as to the dis-
ease burden or administration of palliative chemotherapy.
HRQoL outcomes combined with survival data (expressed
as QALYs) showed that patients whose recurrence was
treated surgically gained on average 14·0 per cent more
QALYs during the 3-year study interval, which can be con-
sidered a substantial and clinically important health gain.
The present data showed a superior overall HRQoL
in the ﬁrst 3 years after surgical treatment of metastatic
colorectal cancer compared with chemotherapy, which
supports an aggressive surgical approach to colorectal liver
metastases, when feasible. Furthermore, when recurrent
disease was diagnosed, patients who underwent a second
surgical intervention had a better HRQoL than those
who were treated with chemotherapy. This supports an
intensive follow-up scheme to detect recurrent metastatic
disease at an early stage, thus maximizing the chance of
resectability.
It was also observed that patients undergoing non-
curative (futile) laparotomy had a signiﬁcant deterioration
in HRQoL, which did not recover to baseline. These
data conﬁrm earlier observations that non-curative
laparotomy had a more severe impact on patients’
well-being than primary denial of surgical treatment12.
In the present study, the percentage of non-curative
laparotomies (14·0 per cent) was similar to that reported in
a recent multicentre study in a comparable patient group;
16·4 per cent of the latter patients did not undergo planned
hepatic resection21.
In the present study, no standard adjuvant chemotherapy
was given after hepatic surgery.Data on overall and disease-
free survival presented here are similar to those observed
with no additional treatment in most recent studies
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comparing adjuvant chemotherapy with no additional
treatment21,22. Hence, the data on HRQoL in this series
may be applicable to other studies as well.
The most commonly applied HRQoL instruments, such
as the EORTC QLQ-C30 and the Functional Assessment
of Cancer Therapy – G (and their modules), produce
descriptive proﬁle measures encompassing multiple health
domains23. The same holds for supplementary modules
of the EORTC QLQ-C3024. Instruments in this class
are based predominantly on the classical test theory
measurement model, which estimates the level of a health
domain as the sum of responses to individual items25.
Preferably, HRQoL measures should allow computational
procedures and parametric statistical testing. This is
facilitated when outcome measures are at least at the
interval level26, meaning that the metric of the HRQoL
scale is continuous. In fact, the underlying rationale for the
value-based HRQoL approach used in this study was to
derive such qualiﬁedHRQoLmeasures. From a theoretical
point of view, the value-based approach is more in line
with measurement theories27. Until now, it has rarely been
applied as an HRQoL measure in clinical studies, but
used predominantly by health economists in the context
of cost-effectiveness analysis. Yet the value-based HRQoL
approach is conceptually identical to the index approach
advocated by clinimetrics28,29.
A drawback of the generic value-based HRQoL
instruments is that they are all based on a limited set of
health domains and often lack relevant domains for speciﬁc
diseases. This may explain the recent interest in developing
disease-speciﬁc value-based HRQoL instruments5,30. At
present, it seems that generic value-based instruments and
descriptive (proﬁle) HRQoL measures are both necessary
to discern the overall impact and the disease-speciﬁc
domains that contribute to this. The present study can be
regarded as an example of how these HRQoL instruments
can assess the value of speciﬁc interventions in surgical
oncology.
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Commentary
Long-term global quality of life in patients treated for colorectal liver
metastases (Br J Surg 2011; 98: 565–571)
Surgery for colorectal liver metastases is becoming increasingly common, and surgeons need to understand the beneﬁts
and risks of resection from the patients’ perspective when offering treatment. Obtaining information from well designed
studies to inform patients fully of outcomes is difﬁcult, however, because measurement of patients’ views leads to additional
complexities of data collection, analysis and interpretation. The present linked multicentre cohort study is an excellent
example of how patient-reported outcomes can be used to evaluate surgery. Validated, brief health-related quality-of-life
(HRQoL) measures were completed in hospital before surgery and distributed by post, with reminders during follow-up
to ensure that data were reliable and compliance high. To avoid reporting bias and missing data, clinical and operative
outcomes were documented prospectively using standard forms, and quality-adjusted life years (QALYs) were calculated
to inform health policy.
The above factors ensure that the work is relevant to patients, surgeons and health policy makers, but several issues
need elucidation. The study did not use a disease-speciﬁc measure of HRQoL, and problems such as postoperative fatigue
may have been missed. Patients undergoing perioperative chemotherapy were not included and the impact of this on
HRQoL remains unknown, although it is currently being addressed in the New EPOC trial1. The study did emphasize a
HRQoL beneﬁt from further resection of recurrent disease compared with administration of further chemotherapy, but
randomized data are needed to make an unbiased comparison. Finally, for results to impact on clinical decision-making,
it is necessary to communicate HRQoL data effectively to patients alongside clinical outcomes2.
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Whether it is possible to do this by providing information about HRQoL domains (such as symptoms or function) and
survival data separately, or whether patients better understand a composite score of HRQoL and survival in the form of a
QALY is unknown, and this needs addressing for these data to be used in a real life setting.
J. M. Blazeby




1 New EPOC. An open-label, randomised, multi-centre prospective trial of oxaliplatin/irinotecan plus ﬂuoropyrimidine versus
oxaliplatin/irinotecan plus ﬂuoropyrimidine and cetuximab pre and post operatively in patients with resectable colorectal liver
metastases requiring chemotherapy. http://www.ctu.soton.ac.uk/trial.aspx [accessed 20 October 2010].
2 McNair AG, Brookes ST, Davis CR, Argyropoulos M, Blazeby JM. Communicating the results of randomized clinical trials: do
patients understand multidimensional patient-reported outcomes? J Clin Oncol 2010; 28: 738–743.
Trauma issue of BJS
Call for papers
Many general surgeons are still responsible for the management of trauma in their hospitals, and we are often asked to
include more articles about trauma in BJS. This year, BJS will publish a thirteenth issue focusing on trauma for the
general surgeon. The issue will contain a mix of invited and submitted articles, and will be managed by a Guest Editor.
Readers who would like to offer material for this issue should prepare papers in standard BJS style, and submit them to
the Journal before 1st June 2011. The papers will be managed in the usual way via the BJS electronic manuscript handling
system, and will be subject to standard peer review.
For further details or information, please contact the BJS Editorial Ofﬁce
(E-mail: bjs@wiley.co.uk).
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